荷兰术中高频振荡或棘波引导癫痫手术的随机单盲适应性非劣效性试验(HFO试验)
HFO试验在荷兰一家癫痫手术中心随机分配78例患者,比较术中高频振荡(HFO)引导与棘波引导裁剪癫痫手术的1年无发作率。HFO组26/39(67%)无发作,棘波组35/39(90%),风险差-23.5%(90%CI -39.1至-7.9),未达非劣效。校正混杂后,颞叶外癫痫中HFO显示非劣效。
要点
- HFO引导裁剪在全体人群中未达到对棘波引导的非劣效性。
- 颞叶癫痫风险差-25.5%,颞叶外癫痫风险差-20.3%,后者校正后非劣效。
- 作者认为该试验挑战HFO作为癫痫生物标志物的临床价值,尤其颞叶癫痫。
核心结论
- HFO引导的癫痫手术裁剪在术中 electrocorticography 上对棘波引导裁剪未达到非劣效性。
- 校正混杂因素后,HFO在颞叶外癫痫中显示非劣效性。
- 该试验挑战HFO作为癫痫生物标志物的临床价值,尤其在颞叶癫痫。
- 需要进一步研究以确定HFO引导的术中 electrocorticography 在颞叶外癫痫中是否有前景。
研究设计与样本
- HFO试验是一项在荷兰癫痫手术中心(UMC Utrecht)进行的随机、单盲、适应性非劣效性试验。
- 招募转诊接受术中 electrocorticography 裁剪癫痫手术的儿童和成人(无年龄限制)。
- 参与者按1:1随机分配至HFO引导或棘波引导裁剪,使用在线随机化方案,由独立数据管理者生成排列区组,按癫痫类型分层。
- 治疗分配对参与者和记录癫痫结果的临床医生设盲,但对研究团队或神经外科医生不设盲。
- 预先设定的非劣效性界值为10%风险差,分析采用意向性治疗。
主要发现
- 2014年10月10日至2020年1月31日,共78人入组并随机分配(HFO引导组39人,棘波引导组39人),无失访。
- 1年无发作在HFO引导组为26/39(67%),在棘波引导组为35/39(90%),风险差-23.5%(90%CI -39.1至-7.9)。
- 48例颞叶癫痫患者的风险差为-25.5%(90%CI -45.1至-6.0),30例颞叶外癫痫患者为-20.3%(90%CI -46.0至5.4)。
- 与不良预后相关的病理被确定为混杂因素,校正后风险差为-7.9%(90%CI -20.7至4.9);颞叶癫痫校正后风险差-12.5%(90%CI -31.0至5.9),颞叶外癫痫为5.8%(90%CI -7.7至19.5)。
- 记录到8例严重不良事件(HFO引导组5例,棘波引导组3例)需要住院,无患者死亡。
临床怎么用
- 原文未据此给出推荐。
局限性
- 需要进一步研究以确定HFO引导的术中 electrocorticography 在颞叶外癫痫中是否有前景。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Intraoperative electrocorticography is used to tailor epilepsy surgery by analysing interictal spikes or spike patterns that can delineate epileptogenic tissue. High-frequency oscillations (HFOs) on intraoperative electrocorticography have been proposed as a new biomarker of epileptogenic tissue, with higher specificity than spikes. We prospectively tested the non-inferiority of HFO-guided tailoring of epilepsy surgery to spike-guided tailoring on seizure freedom at 1 year. METHODS: The HFO trial was a randomised, single-blind, adaptive non-inferiority trial at an epilepsy surgery centre (UMC Utrecht) in the Netherlands. We recruited children and adults (no age limits) who had been referred for intraoperative electrocorticography-tailored epilepsy surgery. Participants were randomly allocated (1:1) to either HFO-guided or spike-guided tailoring, using an online randomisation scheme with permuted blocks generated by an independent data manager, stratified by epilepsy type. Treatment allocation was masked to participants and clinicians who documented seizure outcome, but not to the study team or neurosurgeon. Ictiform spike patterns were always considered in surgical decision making. The primary endpoint was seizure outcome after 1 year (dichotomised as seizure freedom [defined as Engel 1A-B] vs seizure recurrence [Engel 1C-4]). We predefined a non-inferiority margin of 10% risk difference. Analysis was by intention to treat, with prespecified subgroup analyses by epilepsy type and for confounders. This completed trial is registered with the Dutch Trial Register, Toetsingonline ABR.NL44527.041.13, and ClinicalTrials.gov, NCT02207673. FINDINGS: Between Oct 10, 2014, and Jan 31, 2020, 78 individuals were enrolled to the study and randomly assigned (39 to HFO-guided tailoring and 39 to spike-guided tailoring). There was no loss to follow-up. Seizure freedom at 1 year occurred in 26 (67%) of 39 participants in the HFO-guided group and 35 (90%) of 39 in the spike-guided group (risk difference -23·5%, 90% CI -39·1 to -7·9; for the 48 patients with temporal lobe epilepsy, the risk difference was -25·5%, -45·1 to -6·0, and for the 30 patients with extratemporal lobe epilepsy it was -20·3%, -46·0 to 5·4). Pathology associated with poor prognosis was identified as a confounding factor, with an adjusted risk difference of -7·9% (90% CI -20·7 to 4·9; adjusted risk difference -12·5%, -31·0 to 5·9, for temporal lobe epilepsy and 5·8%, -7·7 to 19·5, for extratemporal lobe epilepsy). We recorded eight serious adverse events (five in the HFO-guided group and three in the spike-guided group) requiring hospitalisation. No patients died. INTERPRETATION: HFO-guided tailoring of epilepsy surgery was not non-inferior to spike-guided tailoring on intraoperative electrocorticography. After adjustment for confounders, HFOs show non-inferiority in extratemporal lobe epilepsy. This trial challenges the clinical value of HFOs as an epilepsy biomarker, especially in temporal lobe epilepsy. Further research is needed to establish whether HFO-guided intraoperative electrocorticography holds promise in extratemporal lobe epilepsy. FUNDING: UMCU Alexandre Suerman, EpilepsieNL, RMI Talent Fellowship, European Research Council, and MING Fund.
引用
- Zweiphenning W, Klooster MAV', van Klink NEC, et al. Intraoperative electrocorticography using high-frequency oscillations or spikes to tailor epilepsy surgery in the Netherlands (the HFO trial): a randomised, single-blind, adaptive non-inferiority trial. Lancet Neurol. 2022. PMID: 36270309. doi:10.1016/S1474-4422(22)00311-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。